XBiotech Inc. (XBIT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5217 WINNEBAGO LANE AUSTIN, TX 78744 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 172,677 | 200,023 | 217,478 | 236,983 | 237,366 | 714,594 | |||
| Cash and cash equivalent | 172,677 | 200,023 | 157,306 | 236,983 | 237,366 | 714,594 | |||
| Short-term investments | 60,172 | ||||||||
| Receivables | 858 | 935 | 1,764 | 8,953 | 10,687 | ||||
| Other undisclosed current assets | 1,032 | 760 | 601 | 934 | 77,822 | 1,669 | |||
| Total current assets: | 174,567 | 201,718 | 219,843 | 246,870 | 325,875 | 716,263 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 24,526 | 24,897 | 26,260 | 28,307 | 27,336 | 25,171 | |||
| Deferred income tax assets | 533 | 443 | |||||||
| Other undisclosed noncurrent assets | 75,000 | ||||||||
| Total noncurrent assets: | 24,526 | 24,897 | 26,260 | 28,307 | 27,869 | 100,614 | |||
| TOTAL ASSETS: | 199,093 | 226,615 | 246,103 | 275,177 | 353,744 | 816,877 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4,855 | 6,017 | 4,011 | 3,453 | 3,984 | 55,690 | |||
| Taxes payable | ✕ | ✕ | ✕ | ✕ | 10 | 142 | 49,361 | ||
| Accounts payable | 2,223 | 2,516 | 2,408 | 2,069 | 2,491 | 2,149 | |||
| Accrued liabilities | 2,632 | 3,501 | 1,603 | 1,374 | 1,351 | 4,180 | |||
| Deferred revenue | 4,500 | ||||||||
| Other undisclosed current liabilities | 10,250 | 83 | 55 | ||||||
| Total current liabilities: | 15,105 | 6,100 | 4,066 | 3,453 | 3,984 | 60,190 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 1,720 | 1,669 | 1,635 | 2,339 | 1,121 | 1,056 | |||
| Accounts payable and accrued liabilities | 1,720 | 1,669 | 1,576 | 1,466 | 1,121 | 1,056 | |||
| Deferred income tax liabilities | 59 | 873 | |||||||
| Total noncurrent liabilities: | 1,720 | 1,669 | 1,635 | 2,339 | 1,121 | 1,056 | |||
| Total liabilities: | 16,825 | 7,769 | 5,701 | 5,792 | 5,105 | 61,246 | |||
| Equity | |||||||||
| Equity, attributable to parent | 182,268 | 218,846 | 240,402 | 269,385 | 348,639 | 755,631 | |||
| Common stock | 273,105 | 271,152 | 267,325 | 262,263 | 249,805 | 324,808 | |||
| Accumulated other comprehensive income (loss) | 826 | 1,971 | 1,266 | (106) | |||||
| Retained earnings (accumulated deficit) | (90,837) | (52,306) | (27,749) | 5,151 | 97,568 | 430,929 | |||
| Total equity: | 182,268 | 218,846 | 240,402 | 269,385 | 348,639 | 755,631 | |||
| TOTAL LIABILITIES AND EQUITY: | 199,093 | 226,615 | 246,103 | 275,177 | 353,744 | 816,877 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 4,010 | 18,394 | 43,997 | |||||
| Cost of revenue (Cost of Product and Service Sold) | (651) | (5,820) | (34,548) | |||||
| Gross profit: | 3,359 | 12,574 | 9,449 | |||||
| Operating expenses | (42,471) | (37,510) | (37,849) | (37,656) | (27,725) | (31,233) | ||
| Operating loss: | (42,471) | (37,510) | (34,490) | (25,082) | (18,276) | (31,233) | ||
| Nonoperating income (expense) | 3,908 | 13,197 | 902 | (376) | 5,449 | 749,686 | ||
| Investment income, nonoperating | 9,812 | 10,421 | 3,823 | 467 | 2,456 | 750,564 | ||
| Gain (loss), foreign currency transaction, before tax | (5,529) | 1,893 | (2,800) | (711) | 3,496 | (888) | ||
| Other nonoperating income (expense) | 432 | 883 | (121) | (132) | (503) | 10 | ||
| Income (loss) from continuing operations before income taxes: | (38,563) | (24,313) | (33,588) | (25,458) | (12,827) | 718,453 | ||
| Income tax expense (benefit) | 32 | (244) | 688 | 8,044 | 1,606 | (49,824) | ||
| Income (loss) from continuing operations: | (38,531) | (24,557) | (32,900) | (17,414) | (11,221) | 668,629 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (17,414) | (11,221) | 668,629 | |
| Net income (loss) available to common stockholders, diluted: | (38,531) | (24,557) | (32,900) | (17,414) | (11,221) | 668,629 | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (38,531) | (24,557) | (32,900) | (17,414) | (11,221) | 668,629 | ||
| Comprehensive income (loss): | (38,531) | (24,557) | (32,900) | (17,414) | (11,221) | 668,629 | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (826) | (1,145) | 705 | 1,372 | 149 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (38,531) | (25,383) | (34,045) | (16,709) | (9,849) | 668,778 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.